54 Chapter 4 References [1] Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090–8. https://doi.org/10.1016/S1470-2045(15)00040-6. [2] Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681–92. https://doi.org/10.1016/S14702045(11)70142-5. [3] Van Den Bogaard VAB, Ta BDP, Van Der Schaaf A, Bouma AB, Middag AMH, Bantema-Joppe EJ, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol 2017;35:1171–8. https://doi.org/10.1200/JCO.2016.69.8480. [4] Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987–98. https://doi.org/10.1056/NEJMoa1209825. [5] Beukema JC, van Luijk P, Widder J, Langendijk J a., Muijs CT. Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? Radiother Oncol 2015;114:85–90. https://doi. org/10.1016/j.radonc.2014.11.037. [6] Ogino I, Watanabe S, Sakamaki K, Ogino Y, Kunisaki C, Kimura K. Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer. Strahlentherapie Und Onkol 2017;193:552–60. https://doi.org/10.1007/s00066-017-1127-8. [7] Ogino I, Watanabe S, Iwahashi N, Kosuge M, Sakamaki K, Kunisaki C, et al. Symptomatic radiationinduced cardiac disease in long-term survivors of esophageal cancer. Strahlentherapie Und Onkol 2016:359–67. https://doi.org/10.1007/s00066-016-0956-1. [8] Lund M, Alexandersson von Döbeln G, Nilsson M, Winter R, Lundell L, Tsai J a, et al. Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction – a prospective cohort pilot study within a randomized clinical trial. Radiat Oncol 2015;10:1–9. https://doi.org/10.1186/s13014-014-0310-7. [9] Umezawa R, Ota H, Takanami K, Ichinose A, Matsushita H. MRI fi ndings of radiation-induced myocardial damage in patients with oesophageal cancer. Clin Radiol 2014;69:1273–9. https:// doi.org/10.1016/j.crad.2014.08.010. [10] Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p. Lancet Oncol 2015;16:187–99. https://doi. org/10.1016/S1470-2045(14)71207-0. [11] Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, et al. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer. J Thorac Oncol 2017;12:293–301. https://doi.org/10.1016/j.jtho.2016.09.134. [12] Lin SH, Zhang N, Godby J, Wang J, Marsh GD, Liao Z, et al. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer 2016;122:917– 28. https://doi.org/10.1002/cncr.29857. [13] Stam B, Peulen H, Guckenberger M, Mantel F, Hope A, Werner-Wasik M, et al. Dose to heart substructures is associated with non-cancer death after SBRT in stage I–II NSCLC patients. Radiother Oncol 2017;123:370–5. https://doi.org/10.1016/j.radonc.2017.04.017. [14] Atkins KM, Rawal B, Chaunzwa TL, Lamba N, Bitterman DS, Williams CL, et al. Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer. J Am Coll Cardiol 2019;73:2976–87. https://doi.org/10.1016/j.jacc.2019.03.500.
RkJQdWJsaXNoZXIy MTk4NDMw